Meibomian Gland Dysfunction - Pipeline Insight, 2021

Meibomian Gland Dysfunction - Pipeline Insight, 2021

  • September 2021 •
  • 60 pages •
  • Report ID: 6133946 •
  • Format: PDF
“Meibomian Gland Dysfunction – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Meibomian Gland Dysfunction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Meibomian Gland Dysfunction Understanding

Meibomian Gland Dysfunction: Overview
Meibomian glands are the tiny oil glands which line the margin of the eyelids (the edges which touch when the eyelids are closed). These glands secrete oil which coats the surface of our eyes and keeps the water component of our tears from evaporating (drying out). Together, the water and the oil layer make up the tear film. Meibomian gland dysfunction (MGD) refers to the condition where the glands are not secreting enough oil or when the oil they secrete is of poor quality. Often, the oil gland openings get plugged up so that less oil comes out of the glands. The oil that does make it out of the glands can be granular (crusty) or otherwise unhealthy and can cause irritation. The symptoms of meibomian gland dysfunction — red eyes, a gritty feeling, itchy eyes, and blurred vision — are nearly the same as those of dry eye syndrome. The clinical diagnosis of MGD is often made using a combination of subjective symptoms and clinical signs. If asymptomatic, the diagnosis of MGD is only detectable by the presence of clinical signs. In the past, the typical treatment recommended for MGD was applying warm compresses to the eyelids, followed by massaging the eyelids. The goal of this treatment was to melt and express any thickened oil clogging the openings of meibomian glands.

"Meibomian Gland Dysfunction - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Meibomian Gland Dysfunction pipeline landscape is provided which includes the disease overview and Meibomian Gland Dysfunction treatment guidelines. The assessment part of the report embraces, in depth Meibomian Gland Dysfunction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meibomian Gland Dysfunction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Meibomian Gland Dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve Meibomian Gland Dysfunction.

Meibomian Gland Dysfunction Emerging Drugs Chapters
This segment of the Meibomian Gland Dysfunction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Meibomian Gland Dysfunction Emerging Drugs
• AZR-MD-001: Azura Ophthalmics
Azura’s lead product candidate, AZR-MD-001, is a topical ointment that has been developed to yield properties ideal for ophthalmic use. The formulation is applied to the lower lid margin before bedtime. Azura is currently evaluating the safety, tolerability and effectiveness of AZR-MD-001, developed for ophthalmic use, in phase II/III trials in patients with MGD. AZR-MD-001 leverages SeS2 as the active ingredient. SeS2 has a triple mechanism of action: it slows down keratin production; breaks down the bonds between abnormal keratin proteins; and increases the quantity of lipid produced by the Meibomian glands. If approved, AZR-MD-001 will be a first-in-class ophthalmic keratolytic for the treatment of lid margin diseases, starting with MGD and CLD.
Further product details are provided in the report……..

Meibomian Gland Dysfunction: Therapeutic Assessment
This segment of the report provides insights about the different Meibomian Gland Dysfunction drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Meibomian Gland Dysfunction
There are approx. 5+ key companies which are developing the therapies for Meibomian Gland Dysfunction. The companies which have their Meibomian Gland Dysfunction drug candidates in the most advanced stage, i.e. Phase II/III include, Azura Ophthalmics.
• Phases
This report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Meibomian Gland Dysfunction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Meibomian Gland Dysfunction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meibomian Gland Dysfunction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meibomian Gland Dysfunction drugs.

Meibomian Gland Dysfunction Report Insights
• Meibomian Gland Dysfunction Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Meibomian Gland Dysfunction Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Meibomian Gland Dysfunction drugs?
• How many Meibomian Gland Dysfunction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meibomian Gland Dysfunction?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Meibomian Gland Dysfunction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Meibomian Gland Dysfunction and their status?
• What are the key designations that have been granted to the emerging drugs?